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Reply
To the Editors:
We appreciate the interest from
Carrieri et al and their comments regard-
ing our article about the effect of
different alcohol consumption levels on
HIV surrogate markers in the Swiss
HIV Cohort Study (SHCS).1 Carrieri
et al conducted a similar longitudinal
analysis using data from the French
ANRS APROCO-COPILOTE CO-08
cohort. In contrast to our study, they
found in 1108 individuals with 11
years of follow-up that low alcohol
consumption levels were associated
with higher CD4 cell counts, whereas
alcohol abstinence and higher levels of
alcohol consumption were associated
with lower CD4 counts. No signiﬁcant
association between alcohol consump-
tion and virological failure was found
in both cohorts.
Some important issues raised
merit a few comments.
Follow-up period was indeed short-
er in our study (median follow-up 2.5
years) compared with that in the French
cohort (median follow-up 6.9 years). This
time difference could possibly explain
why in the SHCS no inﬂuence of alcohol
on CD4 cell counts was observed because
the toxic effect of alcohol needs time to
evolve. However, despite the shorter
follow-up period, we had a larger sample
size (n = 2982 vs. n = 1108 in the French
cohort) and our cohort also has an excel-
lent follow-up where individuals are
asked about alcohol consumption every
6 months and only very few missing data
are recorded (,1%). Carrieri et al did not
specify the frequency of the alcohol as-
sessments and the level of missing data in
the French cohort.
Most importantly, we would like
to highlight that the 2 studies cannot be
compared one to one because different
baselines were used. Individuals in our
study were antiretroviral therapy (ART)
naive and initiated ﬁrst ART. The
French cohort, however, used “protease
inhibitor initiating date” as baseline and
only 45% were ART naive at baseline.
This could cause a problem in model
ﬁtting because individuals at different
stages of ART treatment have different
trajectories for both HIV viral load and
CD4 cell counts. In particular, the deﬁ-
nition for virological failure used in both
studies would only be appropriate in the
ART initiation period. As a consequence,
individuals in the French cohort were
more heterogeneous with a longer
period since HIV diagnosis (3.8 years
vs. 1.0 years) and more AIDS events
(21% vs. 13%). Furthermore, the French
cohort had more injecting drug users
(17% vs. 7%) and individuals co-
infected with hepatitis C virus (22%
vs. 10%). One could argue that individ-
uals in the French cohort were sicker
and more often at risk of severe alcohol
drinking and therefore of nonadherence
to ART. However, we do not have infor-
mation on treatment interruption and
adherence to ART in the French cohort.
Furthermore, in the French
cohort, different categories for alcohol
consumption were used from what we
used. We applied the categories of the
World Health Organization2: low con-
sumption was ,20 g/d for women
and ,40 g/d for men, moderate 20–
40 g/d for women and 40–60 g/d for
men, and severe .40 g/d for women
and .60 g/d for men, whereas in the
French study, low alcohol consump-
tion was ,10 g/d for both men and
women, moderate 10–30 g/d for
women and 10–40 g/d for men, and
severe .30 g/d for women and .40
g/d for men, respectively. Therefore,
if the French deﬁnition would be
applied to our cohort, there would be
fewer individuals categorized in the
moderate drinking group in favor of
the high drinking group. Compared
with the French study, we had 46%
nondrinkers (vs. 19%), 46% light
health risk drinkers (vs. 54%), 5%
moderate (vs. 21%), and 2% severe
health risk drinkers (vs. 6%). Thus,
in our cohort, there were signiﬁcantly
more nondrinkers and indeed fewer
individuals with severe health risk
drinking, limiting possibly the power
in the latter category; the same was
true for moderate health risk drinkers.
But we would also like to rectify the
comment made by Carrieri et al that
we collapsed the categories of low
and moderate health risk drinking,
which is not the case. We fused the
categories of none and light health risk
drinkers, because both of them gave
similar results for CD4 cell counts
and HIV viral loads in the single
analysis.
Besides the alcohol drinking quan-
tity, the drinking pattern also plays an
important role. Binge drinking is known
to be associated with worse prognosis
concerning morbidity and mortality
from alcohol-induced problems and
adherence to ART.3,4 Furthermore, the
type of the consumed alcohol might also
be important in predicting health out-
comes.5 For the French paradox, red
wine was shown to be associated with
lower cardiovascular mortality, whether
this is true for hard liquor as well is
unknown.6,7 As in both cohorts neither
the drinking pattern nor the type of the
consumed alcohol is known, no conclu-
sions can be drawn.
The U-shaped curve between alco-
hol consumption levels and CD4 cell
counts as shown by Carrieri et al8 was
found by the same research team for car-
diovascular mortality, the so-called
French paradox. According to our patho-
physiological understanding and also in
animal models, it is difﬁcult to explain
the U-shaped association between alco-
hol and CD4 cell counts. It is not clear
how a postulated cytotoxic effect of alco-
hol can be protective for CD4 cells at
a certain low level, but being toxic below
and above this level.9–11
Overall, this French study contrib-
utes to the ongoing controversy whether
alcohol has an inﬂuence on HIV surro-
gate markers or not. Both studies are
well and carefully performed and
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therefore justify attention in the discus-
sion of the inﬂuence of alcohol on CD4
cell counts and HIV viral loads.
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Plasma
Lipopolysaccharide
and Triglycerides are
Independently
Associated and Both
Markers Correlate With
the Development of
Metabolic Syndrome in
HIV Infection
To the Editors:
With the widespread introduction
of antiretroviral therapy (ART), non-
AIDS–related mortality today exceeds
the AIDS-related mortality in popula-
tions with access to ART.1 The adjusted
relative risk for cardiovascular disease
is reported to be around 1.5- to 2-fold
compared with that of the general pop-
ulation.2,3 Although classical cardiovas-
cular risk factors such as smoking, the
metabolic syndrome and its isolated
components (dyslipidemia, hypertrigly-
ceridemia, high blood pressure, central
obesity, and hyperglycemia)4 are com-
mon in HIV-infected cohorts and lead-
ing causes of cardiovascular disease in
the HIV-infected population, it has been
suggested that chronic immune activa-
tion and low-grade inﬂammation could
contribute to this excess cardiovascular
risk.2 Chronic immune activation and
low-grade inﬂammation may in turn be
triggered by microbial translocation
from a damaged gut.5 With suppressive
ART, we and others have reported
reduced but not normalized levels of
microbial translocation and chronic
immune activation.6–11 Thus, microbial
translocation may be persistent in HIV-
infected individuals, resulting in chronic
low-grade elevation of lipopolysaccha-
ride (LPS).
The metabolic syndrome and ele-
vated plasma triglycerides have recently
been shown to predict mortality in HIV-
infected individuals.12 In HIV seronega-
tive populations, we have observed that
LPS correlated with visceral fat and
other characteristics of the metabolic
syndrome, that is, dyslipidemia, obesity,
blood pressure, and glycemic control.13
In patients receiving ART, we have
reported signiﬁcant positive correlations
between plasma LPS and triglycerides.14
These data are in line with recent obser-
vations of strong correlation between
LPS and fasting triglycerides, and an
inverse relationship to high density lipo-
protein (HDL) cholesterol in the general
population15 and in HIV-infected per-
sons.16 The aim of the present study
was to investigate the putative impact
of LPS and triglycerides on the develop-
ment of other characteristics associated
with the metabolic syndrome in HIV-
infected individuals.
In an exploratory substudy of
a larger longitudinal study on HIV and
hypertension, 42 HIV-infected nondia-
betic patients were recruited. Inclusion
criteria were ART-naive status and
available plasma samples at the time of
nadir CD4 cell count [median age: 42;
interquartile range: 32–46 years; 78%
males, 80% whites, 11.9% hepatitis C
antibody positive, 52.4% smokers, 29%
with diagnosis of AIDS; body mass
index (BMI): 22.4 (20.2–24.3) kg/m2,
estimated glomerular ﬁltration rate
(eGFR): 106 (95–114) mL/min, glucose
5.1 (4.7–5.4) mmol/L, cholesterol 4.6
(4.1–5.3) mmol/L, nadir CD4 cell
count 240 (36–430) cells/mL and HIV
RNA 44,000 (3550–165,000) copies/
mL].17,18 Plasma levels of LPS were
measured at the time of nadir using the
limulus amebocyte lysate assay. The
samples were diluted 10-fold and then
preheated to 68°C for 12 minutes to dis-
solve immune complexes as previously
reported.17
Characteristics associated with the
metabolic syndrome including blood
pressure, glucose, triglycerides, BMI,
uric acid, and HDL cholesterol were
determined at follow-up 5.5 (interquar-
tile range: 3.6–10.2) years later. At the
time of follow-up, 64% of the patients
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